Loriot Y et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med 2023;389(21):1961-71. Abstract

Meric-Bernstam F et al. Efficacy and Safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2023;42(1):47-58. Abstract

Powles T et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;260(10):875-88. Abstract

Powles T et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Annals Oncol 2024;35(6):P485-90. Abstract

Powles TB et al. Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). ESMO 2023;Abstract LBA6.

Van der Heijden MS et al. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study. Genitourinary Cancer Symposium 2024;Abstract 530.

Van der Heijden MS et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N Engl J Med 2023;389:1778-89. Abstract